Human somatic cell/gene therapy "points to consider
Draft is available, FDA announces in Nov. 29 Federal Register. Topics reviewed in the draft, which is dated August 1991, include characterization of cell populations, preclinical safety testing, lot-to-lot manufacturing, control testing and clinical trial considerations. Requests for the document may be addressed to: Congressional, Consumer, and International Affairs Branch (HFB-142), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. Enclose two self-addressed adhesive labels. . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth